Xenon Pharmaceuticals R&D spend
Xenon Pharmaceuticals Inc. · XENE (NASDAQ) · Vancouver, BC · Pharmaceuticals
Latest R&D (CAD)
$420.7M
Period ended 2025-12-31
Revenue (CAD)
$10.5M
4012.5% of revenue · scale $66.4M
R&D by fiscal period
2025
$420.7M
2024
$288.2M
2023
$226.1M
2022
$137.6M
2021
$94.6M
2020
$67.8M
2019
$51.5M
2018
$30.6M
| Period end | R&D (CAD) | Revenue (CAD) | Native R&D | Form | Source |
|---|---|---|---|---|---|
| 2025-12-31 | $420,651,136 | $10,483,500 | $300,938,000 USD | 10-K | SEC EDGAR |
| 2024-12-31 | $288,197,701 | — | $210,394,000 USD | 10-K | SEC EDGAR |
| 2023-12-31 | $226,090,946 | — | $167,512,000 USD | 10-K | SEC EDGAR |
| 2022-12-31 | $137,634,597 | $12,276,464 | $105,767,000 USD | 10-K | SEC EDGAR |
| 2021-12-31 | $94,592,871 | $23,110,780 | $75,463,000 USD | 10-K | SEC EDGAR |
| 2020-12-31 | $67,776,605 | $43,150,689 | $50,523,000 USD | 10-K | SEC EDGAR |
| 2019-12-31 | $51,543,431 | $9,061,400 | $38,845,000 USD | 10-K | SEC EDGAR |
| 2018-12-31 | $30,622,574 | — | $23,634,000 USD | 10-K | SEC EDGAR |